These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16871462)

  • 81. Fluctuating baseline pain implicated in failure of clinical trials.
    Dolgin E
    Nat Med; 2010 Oct; 16(10):1053. PubMed ID: 20930724
    [No Abstract]   [Full Text] [Related]  

  • 82. Pain therapeutics--SMi's Ninth Annual Conference 8-9 June 2009, London, UK.
    Kirkham K
    IDrugs; 2009 Aug; 12(8):489-91. PubMed ID: 19629882
    [No Abstract]   [Full Text] [Related]  

  • 83. Nociception: Taking the Pain out of Drug Discovery. 28 November 2006, London, UK.
    Norman P
    IDrugs; 2007 Feb; 10(2):102-5. PubMed ID: 17285460
    [No Abstract]   [Full Text] [Related]  

  • 84. Pain therapeutics--SMi's seventh annual conference. 12-13 June 2006, London, UK.
    Harrop S
    IDrugs; 2006 Aug; 9(8):548-50. PubMed ID: 16871462
    [No Abstract]   [Full Text] [Related]  

  • 85. The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain.
    Westaway SM
    J Med Chem; 2007 May; 50(11):2589-96. PubMed ID: 17489570
    [No Abstract]   [Full Text] [Related]  

  • 86. [New analgesics coming. Monoclonal NGF antibody takes the lead].
    Claesson A
    Lakartidningen; 2009 Feb 11-17; 106(7):430-4. PubMed ID: 19350769
    [No Abstract]   [Full Text] [Related]  

  • 87. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.
    Davis MP
    Expert Opin Investig Drugs; 2014 Aug; 23(8):1123-40. PubMed ID: 24836296
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Transient receptor potential vanilloid-1 antagonists: a survey of recent patent literature.
    Voight EA; Kort ME
    Expert Opin Ther Pat; 2010 Sep; 20(9):1107-22. PubMed ID: 20586701
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway.
    Gunthorpe MJ; Chizh BA
    Drug Discov Today; 2009 Jan; 14(1-2):56-67. PubMed ID: 19063991
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks.
    Wong GY; Gavva NR
    Brain Res Rev; 2009 Apr; 60(1):267-77. PubMed ID: 19150372
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Future potential and status of selective sodium channel blockers for the treatment of pain.
    Priest BT
    Curr Opin Drug Discov Devel; 2009 Sep; 12(5):682-92. PubMed ID: 19736626
    [TBL] [Abstract][Full Text] [Related]  

  • 92. [Recent advances in the structure-activity relationship study of small-molecule sodium channel blockers with analgesic effects].
    Li W; Zhou Y; Liu HM; You QD
    Yao Xue Xue Bao; 2009 Feb; 44(2):101-8. PubMed ID: 19408676
    [TBL] [Abstract][Full Text] [Related]  

  • 93.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 94.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 95.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.